Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alofec is an investigational allogeneic cell therapy composed of adipose-derived mesenchymal stem cells (ASCs). Developed by the Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS), it is specifically designed for the treatment of faecal incontinence. The therapy involves the local, intrasphincteric injection of these stem cells, which are hypothesized to promote the regeneration of the anal sphincter muscle and modulate local inflammatory responses through paracrine signaling. This regenerative approach aims to restore sphincter function and improve quality of life for patients who have not responded to conventional treatments. Alofec has been evaluated in Phase II clinical trials in Spain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alofec.